Oncology

Patritumab deruxtecan (HER3-DXd)

Daiichi Sankyo / Merck

HER3-directed ADC. HERTHENA-Lung02 Phase 3 met PFS primary endpoint vs chemo in EGFR-mutant NSCLC post-TKI. OS data pending. FDA submission discussions ongoing.

NSCLCEGFR-mutant

Linked Studies

NCT05338970PrimaryACTIVE_NOT_RECRUITINGPHASE3

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Nonsquamous Non-small Cell Lung CancerEGFR L858RUpdated Jan 2025

Loading comments…

Also Known As

Other names

patritumab

Search all trials →Request coverage update